A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at Georgetown University’s Lombardi Comprehensive Cancer Center report that ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
T cells are central to adaptive immunity, orchestrating targeted responses against infections and malignancies while forming a durable immunological memory. Memory T cells, particularly CD8+ subsets, ...
In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...
Lipid nanoparticle (LNP) mRNA vaccines induce robust immune responses and provide protection against infectious diseases. However, this immunity can be short-lived, resulting in the need for frequent ...
Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't respond to this immunotherapy for reasons not yet fully understood.
The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from sub-Saharan Africa. Its ability to induce broad ...
In an interview on treatments following failure of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, Rahul Banerjee, MD outlines the theory behind potential therapeutic strategies ...
Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...
The ability of immune cells—particularly CD8 + T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results